Common aminosalicylates used in IBD include sulfasalazine, balsalazide
, mesalamine, and olsalazine.
Children were defined as having IBD if they had either three or more health care visits for Crohn's disease or ulcerative colitis during the study's time frame, or "at least one health care contact for Crohn's disease or ulcerative colitis and at least one pharmacy claim for any of the following medications: mesalamine, olsalazine, balsalazide
, sulfasalazine, 6-mercaptopurine, azathioprine, methotrexate, enteral budesonide, or biologies (infliximab, adalimumab, certolizumab, or natalizumab).
tablets, Granulated Mesalamine and SANVAR (600 ug vials vapreotide acetate powder) are under development.
Two other agents in this class, balsalazide
(Colazal) and olsalazine (Dipentum), are broken down in the colon to 5-ASA.
Three medicines are used for treating an acute attack: Aminosalicylates (such as balsalazide
, mesalazine, olsalazine, sulfasalazine), Corticosteroids (budesonide, hydrocortisone, prednisolone) and Immunosuppressants (azathioprine, ciclosporin, mercaptopurine) Rest is important during an attack to allow healing to take place.
and azathioprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.
Active UC should be treated initially with systemic aminosalicylate drugs (such as sulfasalazine, olsalazine, balsalazide
, and mesalamine) or with corticosteroids.
In vitro kinetic studies with recombinant human TPMT demonstrated that sulfasalazine, 5-aminosalicylic acid, balsalazide
, and olsalazine (3-5) inhibit the enzyme activity in a noncompetitive manner.
Now physicians and patients can choose either GIAZO utilizing locally acting balsalazide
disodium for the treatment of mildly to moderately active ulcerative colitis or APRISO utilizing once-daily delayed and extended -release mesalamine for the maintenance of remission of ulcerative colitis.
Most physicians now tend to favor the other 5-ASA agents, mesalamine and balsalazide
, for induction therapy because they are better tolerated.
Results showed that after 12 months of therapy for continuing patients, 20 percent of Lialda patients were continually persistent, 9 percent of Asacol(R) (mesalamine) patients, 7 percent (250mg) and 10 percent (500mg) of Pentasa(R) (mesalamine) patients, 10 percent of balsalazide
[combined results from generic balsalazide
disodium and Colazal(R) (balsalazide
disodium)] patients, and 10 percent (500mg) of Dipentum(R) (olsalazine sodium) patients were persistent.
tablets removed from Datamonitor's forecast - Salix turns its attention to Apriso marketing 68